USD10
AVTX Shares
About Avalo TherapeuticsAvalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
USD10
AVTX Shares
About Avalo TherapeuticsAvalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Stats
TRADING WINDOW
Closed
OPENS AT
Sep 2 at 1:30 PM GMT+0
MARKET CAP
$1.02B
OPEN PRICE
Not enough data
LOW (1Y)
$8.65
HIGH (1Y)
$24.27
LOW (24H)
$18.50
HIGH (24H)
$19.70
VOLUME (24H)
$319.9K
67.65%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $18.70 | |
1 Week | $18.50 | |
1 Month | $18.07 | |
1 Year | $10.56 |
Past performance is not a reliable indicator of future results.
Discover more
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.